Otsuka (OTCMKTS:OTSKY) Stock Price Passes Below 50 Day Moving Average – Here’s What Happened

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) shares crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $34.98 and traded as low as $32.50. Otsuka shares last traded at $32.52, with a volume of 50,295 shares.

Analyst Upgrades and Downgrades

OTSKY has been the subject of several recent analyst reports. Zacks Research upgraded Otsuka from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 31st. The Goldman Sachs Group downgraded Otsuka from a “strong-buy” rating to a “strong sell” rating in a research note on Friday, February 27th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.

Otsuka Stock Performance

The firm has a 50 day moving average of $34.98 and a two-hundred day moving average of $32.09. The stock has a market cap of $34.93 billion and a P/E ratio of 13.72. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.67 and a current ratio of 2.17.

Otsuka (OTCMKTS:OTSKY) last announced its earnings results on Tuesday, April 28th. The company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.16. Otsuka had a return on equity of 12.33% and a net margin of 15.01%.The firm had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.78 billion. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. On average, research analysts predict that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.99 EPS for the current fiscal year.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.